Complement factor D inhibitor 1
98%
- Product Code: 108193
CAS:
1386455-76-0
| Molecular Weight: | 483.32 g./mol | Molecular Formula: | C₂₁H₁₉BrN₆O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
This compound is primarily used in the field of immunology and therapeutic research. It acts as a selective inhibitor of complement factor D, a key enzyme in the alternative pathway of the complement system. By inhibiting this enzyme, it helps in controlling the overactivation of the complement system, which is implicated in various inflammatory and autoimmune diseases. Its application is particularly significant in the treatment of conditions like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated disorders. Additionally, it is being investigated for its potential use in reducing inflammation and tissue damage in diseases such as age-related macular degeneration (AMD) and certain kidney diseases. The compound represents a promising approach for targeted therapy in conditions where the complement system plays a critical role.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿70,668.00 |
+
-
|
Complement factor D inhibitor 1
This compound is primarily used in the field of immunology and therapeutic research. It acts as a selective inhibitor of complement factor D, a key enzyme in the alternative pathway of the complement system. By inhibiting this enzyme, it helps in controlling the overactivation of the complement system, which is implicated in various inflammatory and autoimmune diseases. Its application is particularly significant in the treatment of conditions like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated disorders. Additionally, it is being investigated for its potential use in reducing inflammation and tissue damage in diseases such as age-related macular degeneration (AMD) and certain kidney diseases. The compound represents a promising approach for targeted therapy in conditions where the complement system plays a critical role.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :